Melatonin Improves DNA Damage Repair Capacity in Night Shift Workers
By Elana Gotkine HealthDay Reporter
TUESDAY, Feb. 25, 2025 -- For night shift workers, melatonin supplementation seems to improve oxidative DNA damage repair capacity, according to a study published online Feb. 24 in Occupational & Environmental Medicine.
Umaimah Zanif, from the British Columbia Cancer Research Institute in Vancouver, Canada, and colleagues examined whether melatonin supplementation would improve oxidative DNA damage repair among night shift workers in a parallel-arm randomized placebo-controlled trial involving 40 night shift workers. Supplements were consumed before day sleep during a four-week period. Creatinine-adjusted 8-hydroxy-2'-deoxyguanosine (8-OH-dG) measured in urine was an indicator of oxidative DNA damage repair capacity, with higher concentrations indicative of better repair.
The researchers observed a borderline statistically significant 1.8-fold increase in urinary 8-OH-dG excretion during day sleep in association with the melatonin intervention (95 percent confidence interval, 1.0 to 3.2; P = 0.06). During the subsequent night shift, there was no statistically significant difference in 8-OH-dG excretion (melatonin versus placebo excretion ratio, 0.9; 95 percent confidence interval, 0.6 to 1.5; P = 0.7).
"Assessing long-term efficacy is critical since those who work night shifts for many years would need to consistently consume melatonin supplements over that time frame to maximize the potential cancer prevention benefits," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted February 2025
Read this next
Worse Mental Health Trajectories Seen for Survivors of Teen, Young Adult Cancer
WEDNESDAY, May 28, 2025 -- Survivors of adolescent and young adulthood (AYA) cancer have significantly worse mental health trajectories into middle or older adulthood, according...
ASCO: GLP-1 Receptor Agonists May Reduce Risk for Obesity-Related Cancer, All-Cause Death
WEDNESDAY, May 28, 2025 -- For adults with diabetes and obesity, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are associated with a reduced risk for obesity-related...
ASCO: Alcohol-Associated Cancer Mortality Increased From 1990 to 2021
TUESDAY, May 27, 2025 -- Alcohol-associated cancer mortality increased from 1990 to 2021, according to a study presented at the annual meeting of the American Society of Clinical...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.